Types of Tumors

Make selections below to learn more.

Click to Expand

Tumor Types

Pipeline Molecules 1

The compounds and their uses mentioned on this website are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated. 

Phase I

  • Solid Tumor
  • Hematologic
  • Hematologic

Antibody-drug conjugate

(RG6109)

  • Hematologic

Anti-MUC16 TDC

(RG7882)a

  • Gastrointestinal
  • Gynecologic

Anti-TIGIT MAb

(MTGI7192A, RG6058)

 

  • Solid Tumor

Atezolizumab
(anti-PDL1 MAb)

(RG7446)

 

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Gynecologic
  • Hematologic
  • Melanoma
  • Solid Tumor

BET inhibitor

(TEN-010, RG6146)b

 

  • Breast
  • Gynecologic
  • Hematologic
  • Solid Tumor

CD20 TCB

(RG6026)

  • Hematologic

CD20 TDB

(RG7828)

 

  • Hematologic

Cergutuzumab amunaleukin
(CEA-IL2v)

(RG7813)

 

  • Solid Tumor

ChK1 inhibitor

(GDC-0575, RG7741)c

  • Solid Tumor

Cobimetinib
(MEK inhibitor)

(GDC-0973, RG7421)d

 

  • Gastrointestinal
  • Hematologic
  • Solid Tumor

Codrituzumab
(Glypican-3 MAb)

(GC33, RG7686)e

  • Gastrointestinal

Emactuzumab
(CSF-1R MAb)

(RG7155)

 

  • Solid Tumor

FAP-DR5 biMAb

(RG7386)

  • Solid Tumor

FAP-IL2v FP

(RG7461)

  • Breast
  • Genitourinary
  • Solid Tumor

Glypican-3/CD3 biMAb

(CHU)e

  • Solid Tumor

Monoclonal antibody

(RG6160)

 

  • Hematologic

Obinutuzumab

(RG7159)

 

  • Solid Tumor

Pan-RAF inhibitor

(RG6185)

  • Solid Tumor

Personalized cancer vaccine

(RG6180)f

 

  • Solid Tumor

PI3K inhibitor

(GDC-0077, RG6114)

 

  • Breast
  • Solid Tumor

Raf/MEK dual inhibitor

(CHU)e

  • Solid Tumor

Selective estrogen receptor degrader

(SERD [3])

(GDC-9545, RG6171)

 

  • Breast

Selicrelumab
(CD40 MAb)

(RG7876)

 

  • Solid Tumor

Vanucizumab
(ANG2-VEGF biMAb)

(RG7221)

 

  • Gynecologic
  • Solid Tumor

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)g

 

  • Hematologic

Phase II

  • Hematologic

Ipatasertib
(AKT inhibitor)

(GDC-0068, RG7440)c

Find out more about how ipatasertib, an Akt inhibitor, is proposed to work.

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Hematologic
  • Breast

Atezolizumab
(anti-PDL1 MAb)

(RG7446)

 

  • Breast
  • Genitourinary
  • Hematologic

Cobimetinib
(MEK inhibitor)

(GDC-0973, RG7421)d

 

  • Breast
  • Hematologic

Codrituzumab
(Glypican-3 MAb)

(GC33, RG7686)e

  • Gastrointestinal

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)g

 

  • Hematologic

Phase III

  • Hematologic

Ipatasertib
(AKT inhibitor)

(GDC-0068, RG7440)c

Find out more about how ipatasertib, an Akt inhibitor, is proposed to work.

  • Breast
  • Genitourinary
  • Hematologic
  • Breast

Atezolizumab
(anti-PDL1 MAb)

(RG7446)

 

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Gynecologic
  • Melanoma

Cobimetinib
(MEK inhibitor)

(GDC-0973, RG7421)d

 

  • Gastrointestinal

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)g

 

  • Hematologic

aDeveloped in collaboration with Seattle Genetics. bTensha acquisition. cDeveloped in collaboration with Array BioPharma. dDeveloped in collaboration with Exelixis. eDeveloped in collaboration with Chugai. fDeveloped in collaboration with BioNTech. gJoint project with AbbVie.

Reference

1. Roche full-year results 2017 presentation. www.roche.com/dam/jcr:8c13fdde-ea51-431d-9eb1-b6e0a530930f/en/irp180201.pdf. Accessed February 7, 2018.